Back DJ - Search Results

1

Detection of drug bioactivation in vivo: mechanism of nevirapine-albumin conjugate formation in patients.

Meng X, Howarth A, Earnshaw CJ, Jenkins RE, French NS, Back DJ, Naisbitt DJ, Park BK. Meng X, et al. Among authors: back dj. Chem Res Toxicol. 2013 Apr 15;26(4):575-83. doi: 10.1021/tx4000107. Epub 2013 Mar 12. Chem Res Toxicol. 2013. PMID: 23448204

2

The relationship between nevirapine plasma concentrations and abnormal liver function tests.

Almond LM, Boffito M, Hoggard PG, Bonora S, Raiteri R, Reynolds HE, Garazzino S, Sinicco A, Khoo SH, Back DJ, Di Perri G. Almond LM, et al. Among authors: back dj. AIDS Res Hum Retroviruses. 2004 Jul;20(7):716-22. doi: 10.1089/0889222041524670. AIDS Res Hum Retroviruses. 2004. PMID: 15307917

3

Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters.

Maher B, Lloyd J, Wilkins EG, Fraser WD, Back D, Park BK, Pirmohamed M. Maher B, et al. Antivir Ther. 2004 Dec;9(6):879-87. Antivir Ther. 2004. PMID: 15651746 Clinical Trial.

4

Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals.

Almond LM, Edirisinghe D, Dalton M, Bonington A, Back DJ, Khoo SH. Almond LM, et al. Among authors: back dj. Clin Pharmacol Ther. 2005 Aug;78(2):132-42. doi: 10.1016/j.clpt.2005.04.004. Clin Pharmacol Ther. 2005. PMID: 16084848 Clinical Trial.

5

Abacavir forms novel cross-linking abacavir protein adducts in patients.

Meng X, Lawrenson AS, Berry NG, Maggs JL, French NS, Back DJ, Khoo SH, Naisbitt DJ, Park BK. Meng X, et al. Among authors: back dj. Chem Res Toxicol. 2014 Apr 21;27(4):524-35. doi: 10.1021/tx400406p. Epub 2014 Feb 26. Chem Res Toxicol. 2014. PMID: 24571427

6

Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.

Schipani A, Back D, Owen A, Davies G, Khoo S, Siccardi M. Schipani A, et al. Clin Pharmacokinet. 2015 Jan;54(1):107-16. doi: 10.1007/s40262-014-0184-8. Clin Pharmacokinet. 2015. PMID: 25245943

7

Safety perspectives on presently considered drugs for the treatment of COVID-19.

Penman SL, Kiy RT, Jensen RL, Beoku-Betts C, Alfirevic A, Back D, Khoo SH, Owen A, Pirmohamed M, Park BK, Meng X, Goldring CE, Chadwick AE. Penman SL, et al. Br J Pharmacol. 2020 Oct;177(19):4353-4374. doi: 10.1111/bph.15204. Epub 2020 Aug 13. Br J Pharmacol. 2020. PMID: 32681537 Free PMC article. Review.

8

Pharmacokinetic drug interactions with nevirapine.

Back D, Gibbons S, Khoo S. Back D, et al. J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S8-14. doi: 10.1097/00126334-200309011-00003. J Acquir Immune Defic Syndr. 2003. PMID: 14562853

9

Lopinavir protein binding in vivo through the 12-hour dosing interval.

Boffito M, Hoggard PG, Lindup WE, Bonora S, Sinicco A, Khoo SH, Di Perri G, Back DJ. Boffito M, et al. Among authors: back dj. Ther Drug Monit. 2004 Feb;26(1):35-9. doi: 10.1097/00007691-200402000-00008. Ther Drug Monit. 2004. PMID: 14749547 Clinical Trial.

10

Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals.

Almond LM, Hoggard PG, Edirisinghe D, Khoo SH, Back DJ. Almond LM, et al. Among authors: back dj. J Antimicrob Chemother. 2005 Oct;56(4):738-44. doi: 10.1093/jac/dki308. Epub 2005 Sep 1. J Antimicrob Chemother. 2005. PMID: 16141277

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

379 results

Search Page

Filters